A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years

NCT05329051 ·Status: UNKNOWN ·Phase: PHASE2

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine

NCT05239806 ·Status: UNKNOWN ·Phase: PHASE2

The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.

NCT05043285 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.

NCT05043311 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years

NCT05345873 ·Status: UNKNOWN ·Phase: PHASE2

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine

NCT05238454 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines

NCT05323461 ·Status: UNKNOWN ·Phase: PHASE3

Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

NCT05373485 ·Status: COMPLETED ·Phase: PHASE1

An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older

NCT05679466 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)

NCT04352608 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

NCT05373472 ·Status: COMPLETED ·Phase: PHASE2

A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults

NCT05903118 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years

NCT05716347 ·Status: TERMINATED ·Phase: EARLY_PHASE1

Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults

NCT05855408 ·Status: UNKNOWN ·Phase: PHASE4

A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

NCT05394012 ·Status: UNKNOWN ·Phase: PHASE1

A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)

NCT04852705 ·Status: UNKNOWN ·Phase: PHASE3

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.

NCT05354089 ·Status: UNKNOWN ·Phase: PHASE1

The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine

NCT04568811 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine

NCT06754605 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Sequential Enhanced Safety Study of a Novel Coronavirus Messenger RNA (mRNA) Vaccine in Adults Aged 18 Years and Older.

NCT05568693 ·Status: UNKNOWN ·Phase: NA

Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

NCT04530656 ·Status: COMPLETED ·Phase: PHASE1

A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study

NCT05038618 ·Status: COMPLETED ·Phase: PHASE2

A Study of Ad26.COV2.S in Adults (COVID-19)

NCT04436276 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age

NCT05995275 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults

NCT04617483 ·Status: COMPLETED ·Phase: PHASE3